284 related articles for article (PubMed ID: 26276240)
1. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
Fisher M; Petrie MC; Ambery PD; Donaldson J; Ye J; McMurray JJ
Lancet Diabetes Endocrinol; 2015 Sep; 3(9):697-703. PubMed ID: 26276240
[TBL] [Abstract][Full Text] [Related]
2. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Hernandez AF; Green JB; Janmohamed S; D'Agostino RB; Granger CB; Jones NP; Leiter LA; Rosenberg AE; Sigmon KN; Somerville MC; Thorpe KM; McMurray JJV; Del Prato S;
Lancet; 2018 Oct; 392(10157):1519-1529. PubMed ID: 30291013
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
4. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
Ahrén B; Carr MC; Murphy K; Perkins C; Rendell M; Mallory J; Wilson T; Johnson S
Diabetes Res Clin Pract; 2017 Apr; 126():230-239. PubMed ID: 28284167
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
6. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
Pratley RE; Nauck MA; Barnett AH; Feinglos MN; Ovalle F; Harman-Boehm I; Ye J; Scott R; Johnson S; Stewart M; Rosenstock J;
Lancet Diabetes Endocrinol; 2014 Apr; 2(4):289-297. PubMed ID: 24703047
[TBL] [Abstract][Full Text] [Related]
7. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
[TBL] [Abstract][Full Text] [Related]
8. Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.
Green JB; Hernandez AF; D'Agostino RB; Granger CB; Janmohamed S; Jones NP; Leiter LA; Noronha D; Russell R; Sigmon K; Del Prato S; McMurray JJV
Am Heart J; 2018 Sep; 203():30-38. PubMed ID: 30015066
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal safety across the albiglutide development programme.
Leiter LA; Mallory JM; Wilson TH; Reinhardt RR
Diabetes Obes Metab; 2016 Sep; 18(9):930-5. PubMed ID: 27097971
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies.
Marso SP; Lindsey JB; Stolker JM; House JA; Martinez Ravn G; Kennedy KF; Jensen TM; Buse JB
Diab Vasc Dis Res; 2011 Jul; 8(3):237-40. PubMed ID: 21653676
[TBL] [Abstract][Full Text] [Related]
11. PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE.
Al-Kawas F; Anderson MA; Enns R; Wilson TH; Johnson S; Mallory JM
Endocr Pract; 2019 Jul; 25(7):698-716. PubMed ID: 30865522
[No Abstract] [Full Text] [Related]
12. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
Nreu B; Dicembrini I; Tinti F; Sesti G; Mannucci E; Monami M
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1106-1114. PubMed ID: 32448716
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
Rosenstock J; Marx N; Neubacher D; Seck T; Patel S; Woerle HJ; Johansen OE
Cardiovasc Diabetol; 2015 May; 14():57. PubMed ID: 25990013
[TBL] [Abstract][Full Text] [Related]
14. Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Brønden A; Naver SV; Knop FK; Christensen M
Expert Opin Drug Metab Toxicol; 2015; 11(9):1493-503. PubMed ID: 26166682
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
Bethel MA; Patel RA; Merrill P; Lokhnygina Y; Buse JB; Mentz RJ; Pagidipati NJ; Chan JC; Gustavson SM; Iqbal N; Maggioni AP; Öhman P; Poulter NR; Ramachandran A; Zinman B; Hernandez AF; Holman RR;
Lancet Diabetes Endocrinol; 2018 Feb; 6(2):105-113. PubMed ID: 29221659
[TBL] [Abstract][Full Text] [Related]
16. Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.
Davidson JA; Jones-Leone A; Wilson TH; Nino A; Forero-Schwanhaeuser S; Reinhardt RR
Postgrad Med; 2017 Nov; 129(8):849-857. PubMed ID: 29083275
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.
Bruhn D; Martin AA; Tavares R; Hunt B; Pollock RF
J Med Econ; 2016 Jul; 19(7):672-83. PubMed ID: 26882484
[TBL] [Abstract][Full Text] [Related]
18. Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis.
Hoogwerf BJ; Lincoff AM; Rodriguez A; Chen L; Qu Y
Cardiovasc Diabetol; 2016 May; 15():78. PubMed ID: 27188479
[TBL] [Abstract][Full Text] [Related]
19. Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Bonora BM; Avogaro A; Fadini GP
Acta Diabetol; 2019 Sep; 56(9):1051-1060. PubMed ID: 30993527
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.
Brønden A; Knop FK; Christensen MB
Clin Pharmacokinet; 2017 Jul; 56(7):719-731. PubMed ID: 28050889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
